FindTrial
Sign In

A clinical trial to study the role of MRI, gray scale and colour Doppler ultrasound in evaluating how patients with breast cancer respond to chemotherapy given before surgery

Comparing the role of MRI, Gray scale and colour Doppler ultrasound in neoadjuvant chemotherapy response in breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/02/011851
Enrollment
25
Registered
2018-02-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Breast cancer

Interventions

None listed

Sponsors

Dr Rajinder Parshad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Single palpable breast mass before chemotherapy 2. Histologically proven case of breast cancer 3. Patients with locally advanced breast cancer (T3/ T4 with any nodal status) 4. Age of the patient 18 - 65 years 5. Those who give informed written consent for the study

Exclusion criteria

Exclusion criteria: 1. Patients who got 2. Patients who completed 3 cycles of chemotherapy but not operated 3. Patients lost to follow up or expired during or after NACT 4. Patients with distant metastasis and recurrent breast cancer 5. Patient not fit for neoadjuvant chemotherapy or MRI 6. Multicentric or multifocal breast cancer

Design outcomes

Primary

MeasureTime frame
1. To assess the role of MRI with MR spectroscopy in evaluating response to neoadjuvant chemotherapy in locally advanced breast cancer. 2. To assess the role of Gray scale and Colour Doppler ultrasonography in evaluating response to neoadjuvant chemotherapy in locally advanced breast cancer. 3. To compare the above two methods of assessment of response to neoadjuvant chemotherapy in correlation with histopathological evaluationTimepoint: 3 months—

Secondary

MeasureTime frame
Role of MRI and Ultrasonography to assess feasibility of breast conservation surgery post neoadjuvant chemotherapyTimepoint: 3 months—

Countries

India

Contacts

Public ContactDr KarthikP

AIIMS

karthik23mbbs@gmail.com8110086708

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026